«If you can prevent antibody formation in the first place, by finding some way of
producing immunological tolerance that gets around that type of protocol, that would be a major advantage,» says David Lillicrap, a clinician and researcher who specializes in bleeding disorders at Queen's University in Kingston, Ontario, Canada.